Generative design and validation of therapeutic peptides for glioblastoma based on a potential target ATP5A
Hao Qian, Pu You, Lin Zeng, Jingyuan Zhou, Dengdeng Huang, Kaicheng Li, Shikui Tu, Lei Xu · 2025
Read Generative design and validation of therapeutic peptides for glioblastoma based on a potential target ATP5A by Hao Qian, Pu You, Lin Zeng, Jingyuan Zhou, Dengdeng Huang, Kaicheng Li, Shikui Tu, Lei Xu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2512-02030.txt.
Introduction
Glioblastoma is the most aggressive form of brain tumor, and new treatments are urgently needed. Hao Qian and seven co-authors describe a 2025 framework that designs therapeutic peptides, short protein chains, aimed at a potential target protein called ATP5A, then tests the designs in the laboratory.
Their pipeline runs dry to wet: generative models propose peptides first, and experiments validate them afterward. A lead-conditioned generative model focuses the search near known lead peptides, in regions of the right geometry. That focus tames the combinatorial explosion of designing from scratch. The work shows generative design and bench testing closing the loop on a hard cancer target.
Catalog record
| CREATOR | Hao Qian, Pu You, Lin Zeng, Jingyuan Zhou, Dengdeng Huang, Kaicheng Li, Shikui Tu, Lei Xu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2512-02030
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Generative design and validation of therapeutic peptides for glioblastoma based on a potential target ATP5A Hao Qian, Pu You, Lin Zeng, Jingyuan Zhou, Dengdeng Huang, Kaicheng Li, Shikui Tu, Lei Xu Abstract Glioblastoma (GBM) remains the most aggressive tumor, urgently requiring novel therapeutic strategies. Here, we present a dry-to-wet framework combining generative modeling and experimental validation to optimize peptides targeting ATP5A, a potential peptide-binding protein for GBM. Our framework introduces the first lead-conditioned generative model, which focuses exploration on geometrically relevant regions around lead peptides and mitigates the combinatorial complexity of de novo methods. Specifically, we propose POTFlow, a P rior and O ptimal T ransport-based Flow -matching model for peptide optimization. POTFlow employs secondary structure information (e.g., helix, sheet, loop) as geometric constraints, which are further refined by optimal transport to produce shorter flow paths. With this design, our method achieves state-of-the-art performance compared with five popular approaches. When applied to GBM, our method generates peptides that selectively inhibit cell viability and significantly prolong survival in a patient-derived xenograft (PDX) model. As the first lead peptide-conditioned flow matching model, POTFlow holds strong potential as a generalizable framework for therapeutic peptide design. keywords Peptide Design, Glioblastoma, Flow Matching, Generative Models † † equal-contributors: These authors contributed equally to this work. † † equal-contributors: These authors contributed equally to this work. Introduction Glioblastoma (GBM) is an aggressive brain malignancy with rapid cell proliferation, diffuse tissue invasion, and a profoundly immunosuppressive microenvironment Stupp et al. 2005 ; van Solinge et al. 2022 . Despite standard-of-care treatments involving surgical resection followed by radiotherapy and temozolomide chemotherapy, the median survival remains approximately 15 months, with nearly universal recurrence. ATP5A, the alpha subunit and core component of mitochondrial ATP synthase’s catalytic site, has emerged as a promising therapeutic target in GBM owing to its abnormal surface localization and critical role in tumor energy metabolism Xu and Li 2016 ; Watson et al. 2023 . Targeting ATP5A in GBM presents a compelling therapeutic opportunity, yet its atypical surface exposure poses significant challenges for small-molecule drug design. Peptides offer a promising alternative, as their intermediate molecular size and structural flexibility enable them to access protein surfaces that are typically considered undruggable Craik et al. 2013 ; Henninot et al. 2018 ; Wang et al. 2022 . Moreover, peptides exhibit favorable pharmacological properties, including high target specificity, low immunogenicity, and cost-effective synthesis Giordano et al. 2014 ; Fosgerau and Hoffmann 2015 ; Davda et al. 2019 . Traditional peptide design approaches, such as alanine scanning Lefèvre et al. 1997 and combinatorial screening Quartararo et al. 2020 , are constrained by low throughput and the combinatorial explosion of sequence variants Fosgerau and Hoffmann 2015 ; Manning et al. 2010 . Recently, deep learning-based methods have been increasingly adopted to model protein–peptide interactions Bhardwaj et al. 2016 ; Bryant and Elofsson 2022 ; Swanson et al. 2022 ; Cao et al. 2022 ; Bhat et al. 2023 ; Chen et al. 2024 . Besides, deep generative models, such as diffusion Song et al. 2020a ; Song et al. 2020b ; Dhariwal and Nichol 2021 and flow matching models Lipman et al. 2022 ; Liu et al. 2022 , have demonstrated their potential in peptide binder design Li et al. 2024 ; Lin et al. 2024 ; Kong et al. 2024 ; Wang et al. 2024 . Despite recent successes in designing peptide binders, there are still two limitations. First, current deep generative methods focus mainly on generating peptides from scratch, while in practical drug discovery, peptides are typically derived and optimized from lead sequences, as high sequence similarity often correlates with functional similarity Orengo et al. 1999 . Notably, previous studies Li et al. 2023 ; You et al. 2025 elucidated the DDIT4L–TOM40–ATP5A pathway in GBM and designed a DDIT4L-derived peptide that binds ATP5A, impairs mitochondrial ATP synthase activity, and suppresses tumor growth in preclinical models. However, this ATP5A-targeting peptide essentially represents a first-generation lead obtained by motif selection, and its potency and therapeutic window remain suboptimal, underscoring the need for systematic lead optimization. Therefore, designing peptides based on lead sequences is a more reasonable and practically relevant direction. Second, the absence of experimental validation in most computational peptide design methods raises concerns about their practical applicability. To overcome these limitations, we introduce a dry-to-wet peptide design framework for GBM. Unlike de novo methods, our framework explores the local latent space surrounding a lead peptide to identify functionally relevant candidates based on a carefully designed prior. Specifically, we propose a P rior and O ptimal T ransport-based Flow -matching (POTFlow) model for peptide optimization. POTFlow initializes a prior distribution using secondary structure types (e.g., helix, sheet, loop) from the lead peptide as geometric constraints. This prior is further refined via optimal transport to shift the sampling distribution closer to the lead peptide, enabling shorter flow paths and improved optimization performance. Besides, by integrating expert system filtering and experimental validation, our framework bridges in silico peptide design with wet-lab evaluation. When applied to GBM, our framework generated peptides that surpassed the lead in inhibiting cell viability in vitro and exhibited tumor cell selectivity. Moreover, it identified a candidate that significantly suppressed tumor growth in a patient-derived xenograft (PDX) model, highlighting its strong potential for therapeutic peptide design. Methodologically, POTFlow extends multimodal flow matching from unconditional de novo generation to a lead-conditioned optimization regime. To our knowledge, POTFlow is the first lead peptide-conditioned flow-matching frameworks with integrated experimental validation, spanning in silico design, in vitro assays, and in vivo PDX models. Figure 1: Schematic workflow from in silicon peptide design to experimental validation. a) We start from a lead peptide sequence and 3D structure of its target protein. b) POTFlow efficiently samples peptide–protein complexes within the lead peptide-conditioned space. c) An expert system clusters candidate peptides, ranks their binding affinities, and analyzes intermolecular interactions (e.g., hydrogen bonds, water bridges, \pi –stacking). d) Promising candidates are synthesized and tested by cell‐viability assays and patient-derived xenograft (PDX) models. Results An overview of the proposed peptide design framework for glioblastoma We build a deep generative model jointly with experimental analysis in a dry-to-wet framework to design peptide therapeutics for GBM (Fig. 1 ). The core of our framework is POTFlow, the first lead-peptide-driven deep generative model, which fundamentally sets it apart from conventional de novo design methods. De novo design approaches often suffer from inefficiency and low success rates, primarily due to the vast combinatorial search space and the absence of biological context resulting from the use of an unconditional prior. In contrast, POTFlow utilizes the lead peptide to guide and restrict exploration within its local sequence–structure neighborhood (Fig. 1 a–b), thereby focusing the search on geometrically relevant regions and increasing the likelihood of identifying functional candidates. These candidates are subsequently evaluated by an expert system (Fig. 1 c). Top candidates are further synthesized and validated by cell viability assays and patient-derived xenograft (PDX) models (Fig. 1 d). Importantly, our framework bridges computational design with experimental validation which enables efficient translation of in silico design into experimentally validated peptide therapeutics. Figure 2: a) An overview of POTFlow . First, class-specific centroids are computed from lead peptide structures. Here, “class” represents the peptide folding type (e.g.,